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Distribution of Bioactive Lipid Mediators in
Human Skin
Alexandra C. Kendall1, Suzanne M. Pilkington2, Karen A. Massey3, Gary Sassano4, Lesley E. Rhodes2 and
Anna Nicolaou1
The skin produces bioactive lipids that participate in physiological and pathological states, including
homeostasis, induction, propagation, and resolution of inﬂammation. However, comprehension of the
cutaneous lipid complement, and contribution to differing roles of the epidermal and dermal compartments,
remains incomplete. We assessed the proﬁles of eicosanoids, endocannabinoids, N-acyl ethanolamides, and
sphingolipids, in human dermis, epidermis, and suction blister ﬂuid. We identiﬁed 18 prostanoids, 12 hydroxy-
fatty acids, 9 endocannabinoids and N-acyl ethanolamides, and 21 non-hydroxylated ceramides and sphingoid
bases, several demonstrating signiﬁcantly different expression in the tissues assayed. The array of dermal and
epidermal fatty acids was reﬂected in the lipid mediators produced, whereas similarities between lipid proﬁles in
blister ﬂuid and epidermis indicated a primarily epidermal origin of suction blister ﬂuid. Supplementation with
omega-3 fatty acids ex vivo showed that their action is mediated through perturbation of existing species and
formation of other anti-inﬂammatory lipids. These ﬁndings demonstrate the diversity of lipid mediators involved
in maintaining tissue homeostasis in resting skin and hint at their contribution to signaling, cross-support, and
functions of different skin compartments. Proﬁling lipid mediators in biopsies and suction blister ﬂuid can
support studies investigating cutaneous inﬂammatory responses, dietary manipulation, and skin diseases lacking
biomarkers and therapeutic targets.
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INTRODUCTION
The skin is rich in lipids that not only contribute to formation
and maintenance of the epidermal barrier, but also perform
critical roles in membrane structure and the functions
of cutaneous cells. Bioactive lipid mediators are derived
from complex membrane lipids and are produced upon
request and in response to environmental and signaling
stimuli. They contribute to both skin physiology and
pathology, with evidence of involvement in psoriasis,
dermatitis, acne, wound healing, and UV responses (reviewed
in (Kendall and Nicolaou, 2013)). Dermal and epidermal
compartments have diverse roles, while supporting each other
with nutrients and transcellular signals (Edmondson et al., 2003;
Yamaguchi et al., 2005; Yu et al., 2011), and exhibit
considerable inter-family cross talk (Figure 1). Thus, the lipid
complement of human skin and its compartments demand
deﬁnition, to assist understanding of skin biology and to facilitate
diverse applications including assessment of treatment targets in
skin disorders.
Of particular relevance because of their wide range of
potential activities in the skin are the eicosanoid, endocan-
nabinoid, N-acyl ethanolamide, and sphingolipid families.
The eicosanoids are oxygenated metabolites of the 20-carbon
polyunsaturated fatty acids (PUFA) arachidonic acid (AA,
20:4n− 6), eicosapentaenoic acid (EPA; 20:5n−3), and
dihomogamma linolenic acid (DGLA; 20:3n− 6). This family
comprises the cyclooxygenase (COX)-derived prostaglandins
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(PGs), thromboxanes (TXs), and prostacyclin (PGI2), the
lipoxygenase (LOX)–derived leukotrienes (LTs), lipoxins,
E-series resolvins, and hydroxy fatty acids (HFAs), including
hydroxyeicosatetraenoic acids (HETE) and hydroxyeicosapen-
taenoic acids (HEPE), derived from LOX and cytochrome
P450 (CYP)–mediated reactions. Oxygenation of linoleic acid
(LA, 18:2n− 6) gives rise to octadecanoids such as hydroxy-
octadecadienoic acids (HODE), whereas docosahexaenoic
acid (DHA, 22:6n-3) is the precursor of docosanoids such as
D-series resolvins and protectins and hydroxydocosahexae-
noic acids (HDHAs) (reviewed in (Massey and Nicolaou,
2011; Nicolaou, 2013)). A number of PG, HETE, HODE, and
LT have been identiﬁed in human skin and contribute to
keratinocyte proliferation, melanocyte dendricity, photocar-
cinogenesis, allergy, and inﬂammation (Ziboh et al., 2000;
Scott et al., 2004; Honma et al., 2005; Satoh et al., 2006;
Rhodes et al., 2009; Kendall and Nicolaou, 2013).
The endocannabinoids N-arachidonoyl ethanolamide
(anandamide; AEA) and 2-arachidonoyl glycerol (2-AG) are
also derivatives of AA and function as endogenous lipid
ligands of the two cannabinoid receptors (CB), CB1 and CB2
that are expressed throughout the skin in keratino-
cytes, melanocytes, ﬁbroblasts, sebocytes, and hair follicles
(Stander et al., 2005; Dobrosi et al., 2008; McPartland, 2008;
Pucci et al., 2012). Cell and organ culture systems indicate
that endocannabinoids are released by, and alter the func-
tions of, various skin cells (Dobrosi et al., 2008; Toth et al.,
2011; Czifra et al., 2012; Pucci et al., 2012; Sugawara et al.,
2012), and they have been implicated in several cutaneous
pathologies (Kupczyk et al., 2009). A range of N-acyl
ethanolamides (NAEs) can derive from membrane PUFA.
Their relevance to cutaneous biology is illustrated by the
activity of N-palmitoyl ethanolamide (PEA), which has been
implicated in suppression of mast cell degranulation and
inﬂammatory cytokine release, and explored for the treatment
of atopic eczema (Eberlein et al., 2008; Petrosino et al., 2010;
De Filippis et al., 2011).
Sphingolipids are amides of sphingoid bases and an array of
complex species can be derived through addition of fatty
acids and head groups. Species present in the skin include
free sphingoid bases and hundreds of ceramide species, as
well as their phosphorylated versions (Masukawa et al., 2008;
van Smeden et al., 2011; Rabionet et al., 2014; t'Kindt et al.,
2012). The long-chain omega-esteriﬁed ceramides found in
the stratum corneum are considered structural lipids pivotal
for the integrity of the epidermal barrier, and recent studies
have revealed their diversity of structure and physiological
functions (Masukawa et al.., 2008; van Smeden et al., 2011;
Iwai et al., 2012; Janssens et al., 2012; Breiden and Sandhoff,
2014). In contrast, non-hydroxylated ceramides and sphin-
goid bases are important mediators of immune cell regulation,
with roles in homeostasis and inﬂammation (Chalfant and
Spiegel, 2005; Uchida, 2014), and require further investi-
gation to elucidate their contributions in the skin.
The dermis and the epidermis exhibit distinct cell popula-
tions, enzyme proﬁles, and roles, and consequently lipid
mediator expression could differ between the compartments.
Although the epidermis comprises keratinocytes, Langerhans
cells, melanocytes, and Merkel cells, the dermis contains
ﬁbroblasts, immune cells, hair follicles, sweat glands, blood
vessels, and sensory nerves and provides the skin with
elasticity and resistance to mechanical stress. Historically, the
epidermis has been considered more important in terms of
lipid biology because of the lipid-rich nature of the epidermal
barrier. However, the dermis also displays considerable
activity and provides biochemical support to the epidermis,
with mediator cross talk between compartments––e.g. the
epidermis exhibits impaired chain elongation of essential fatty
acids and depends on the dermis for local production of long-
chain PUFA including AA, EPA, and DHA (Chapkin et al.,
1986), whereas dermally derived 15-HETE impairs epidermal
12-LOX activity and dermally produced PGE2 stimulates
keratinocyte proliferation (Kragballe et al., 1986; Conconi
et al., 1996).
Despite increased awareness of the role of lipid mediators
in cutaneous physiology and disease, there is insufﬁcient
information on individual lipid mediator species and their
variation through the skin. To address this, we undertook
comprehensive analysis of (i) eicosanoids and related species,
(ii) endocannabinoids, (iii) N-acyl ethanolamides, and (iv)
non-hydroxylated ceramides and free sphingoid bases, in
human skin tissue and blister ﬂuid, using mass spectrometry-
based targeted mediator lipidomics assays. Our aim was to
assess the production, range, and variation of cutaneous lipid
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Figure 1. Schematic outline of bioactive lipid mediator production and
related signaling events. AA, arachidonic acid; AEA, arachidonoyl
ethanolamide; AP-1, activator protein 1; BLT, leukotriene B4 receptor; CB,
cannabinoid receptor; COX, cyclooxygenase; C1P, ceramide-1-phosphate;
DHA, docosahexaenoic acid; DP, prostaglandin D2 receptor; EP,
prostaglandin E2 receptor; EPA, eicosapentaenoic acid; FA, fatty acid; FA-EA,
fatty acid ethanolamide; G2A, G protein–coupled receptor 132; GPR55, G
protein-coupled receptor 55; HDHA, hydroxydocosahexaenoic acid; HETE,
hydroxyeicosatetraenoic acid; IP, prostacyclin receptor; LOX, lipoxygenase;
LT, leukotriene; LX, lipoxin; NF-κB, nuclear factor of kappa-light-chain-
enhancer in B-cells; PD, protectin; PEA, palmitoyl ethanolamide; PG,
prostaglandin; PLA2, phospholipase A2; PLD, phospholipase D; PPAR,
peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acid;
Rv, resolvin; S1P, sphingosine-1-phosphate; S1P1, sphingosine-1-phosphate
receptor 1; TP, thromboxane receptor; TRPV, transient receptor potential
vanilloid; TX, thromboxane.
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metabolites, including the contributions of dermal and
epidermal compartments, in humans. This valuable informa-
tion can provide insights into the mode of action of bioactive
lipids, including the anti-inﬂammatory omega-3 fatty acids,
and assist understanding of cutaneous biology, with potential
for wide application in skin disease and its treatment.
RESULTS
Eicosanoids in human dermis, epidermis, and blister ﬂuid
Eighteen species of prostanoids and 12 HFA were identiﬁed
and quantiﬁed (Figure 2a; fold changes from dermal to
epidermal expression are presented in Supplementary Table
S1 online). The AA-derived prostaglandins PGE2, PGD2,
PGF2α, and PGI2 (as its stable metabolite 6-keto PGF1α) were
found in all tissues tested, with prevalence signiﬁcantly higher
in the epidermis (P= 0.0003, P= 0.003, P= 0.003, and
P=0.00004, respectively, compared with the dermis); TXA2
(measured as its stable metabolite TXB2) and PGJ2 were
found predominantly in the epidermis. The EPA derived
PGE3, PGD3, and PGF3α, and DGLA derived PGE1 and
PGD1, although identiﬁed in both compartments were higher
in the epidermis. Higher epidermal prevalence was also
observed for all keto- and dihydro-keto PG (e.g. 15-keto-PGE2
and 13,14-dihydro-15-keto-PGE2); these derive from tissue–
speciﬁc catabolic reactions reducing the bioactivity of
primary PG (Tai et al., 2002).
A large number of LOX-derived HFA products of DGLA,
AA, EPA, LA, and DHA were found in both the dermis and the
epidermis (HETrE, HETE, HEPE, HODE, and HDHA, respec-
tively). Interestingly, the LA–derived 9-HODE and 13-HODE
were the predominant species in both compartments,
although found at higher levels in the epidermis (P= 0.015,
P=0.045, respectively) with 9-HODE at mean concentra-
tions of 326.9± 88.2 pg per mg protein in the dermis and
2,728.5± 548.8 pg per mg protein in the epidermis and
13-HODE at 350.6±83.5 pg per mg protein in the dermis and
1,416.7± 201.5 pg per mg protein in the epidermis. Although
13-HODE is considered a 15-LOX product, 9-HODE can
be produced by a partially completed COX-2 reaction
(Laneuville et al., 1995), its levels reﬂecting the high COX
activity observed in both skin compartments. Concentrations
of the 15-LOX products 15-HETrE, and 15-HETE were not
signiﬁcantly different between the dermis and the epidermis
(Figure 2a; P=0.75, P= 0.38= 0.75, and P= 0.38, respec-
tively). Although two more 15-LOX products were identiﬁed
(EPA–derived 15-HEPE and DHA–derived 17-HDHA), these
were not found in all skin samples and their levels were close
to the assay detection limit (20 pg and 10 pg on the column,
respectively, Massey and Nicolaou, 2013). The 5-LOX–
derived product of AA, 5-HETE, was found at a very low
concentration (≤34.7 pg per mg protein) in both the epidermis
and the dermis. The 12-LOX products 12-HETE, 12-HEPE,
13-HDHA, and 14-HDHA were signiﬁcantly higher in the
epidermis (P= 0.002, P=0.027, P= 0.012, and P= 0.04,
respectively) with 12-HETE being one of the predominant
mediators found in both skin compartments (127.3±10.5 pg
per mg protein in the dermis and 570.4± 54.3 pg per mg
protein in the epidermis). The epidermis had higher concen-
trations of 8- and 11-HETE, products of either oxidation or
cutaneous CYP isoforms (Rhodes et al., 2009).
The proﬁle and level of eicosanoids found in suction blister
ﬂuid were similar to that in the epidermis, although with
differences in some species (Figure 2a): 15-deoxy-Δ12,14 PGJ2
was found only in blister ﬂuid, whereas 13,14 dihydro PGE1,
PGJ2, PGD3, and PGF2α, all found in the dermis and
epidermis, appeared to be minor species of blister ﬂuid with
concentrations close to the method detection limit (0.5–5 pg
on the column) (Massey and Nicolaou, 2013).
Endocannabinoids and N-acyl ethanolamides in human dermis,
epidermis, and blister ﬂuid
Nine endocannabinoids and NAE species derivatives of palmitic
acid (PA; C16:0), alpha-linolenic acid (ALA; C18:3n− 3),
linoleic acid (LA; C18:2n−6), oleic acid (OA; C18:1n− 9),
stearic acid (SA; C18:0), EPA, AA, and DHA were quantiﬁed.
Although a larger number of NAE were detected, only those
accurately identiﬁed and quantiﬁed based on the availability
of commercial standards are reported. Both the dermis and
epidermis expressed all species measured, mostly with
comparable expression (Figure 2a). Derivatives of AA, EPA,
and DHA––namely, AEA, eicosapentaenoyl ethanolamide
(EPEA) and docosahexaenoyl ethanolamide (DHEA)––were
signiﬁcantly higher in the epidermis compared with the
dermis (P= 0.016, P= 0.004, and P=0.004, respectively)
(Figure 2a and Supplementary Table S1 online). Finally, all
these metabolites were also present in blister ﬂuid, in ratios
similar to the epidermis.
Ceramides and sphingoid bases in the dermis, epidermis, and
blister ﬂuid
A huge diversity of cutaneous ceramides derives from the
different sphingoid bases and acyl chains (Mizutani et al.,
Figure 2. Expression of eicosanoids, endocannabinoids, and N-acyl ethanolamides (a), and ceramides, phosphorylated ceramides, and sphingoid bases (b), in
human dermis, epidermis, and blister ﬂuid. All lipid mediators were analyzed by LC-MS/MS. The arachidonic acid–derived PGE2, 12-HETE, AEA, and 2-AG and
C18 S and its derivatives C18 S1P, CER[N(22)S(18)], and d18:1/16:0 C1P are provided as example structures of the different classes of lipid mediators presented in
this ﬁgure. Data for prostaglandins (PG), prostacyclin (PGI2) (measured as the stable derivative 6-keto PGF1α), thromboxanes (TX), hydroxy fatty acids,
endocannabinoids, and N-acyl ethanolamides (NAEs) are expressed as pg per mg tissue protein or pg ml−1 blister ﬂuid. Data for ceramides, phosphorylated
ceramides, and sphingoid bases are expressed as pmol per g protein or pmol μl−1 blister ﬂuid (the dermis and epidermis; n= 8 donors; labeled 1–8) and pgml−1
blister ﬂuid (n=3 donors, labeled 9–11). *Po0.05, **Po0.01, and ***Po0.001 when comparing the dermis with the epidermis. C18S: 18-carbon sphingosine
(S); C18DS: 18-carbon dihydrosphingosine (DS); C18S1P: 18-carbon sphingosine-1-phosphate; C18DS1P: 18-carbon dihydrosphingosine-1-phosphate;
Ceramide derivatives of sphingosine (S) with a non-hydroxy fatty acid (N) are named according to the number of carbons of the base (e.g. 16, 18, and so on) and
fatty acid (e.g. 22, 24, and so on). Phosphorylated ceramides are denoted by the base (d18:1 representing sphingosine and d18:0 representing
dihydrosphingosine) and the fatty acid (e.g. 16:0 represents palmitic acid).
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2009; van Smeden et al., 2011; Janssens et al., 2012; t'Kindt
et al., 2012; Rabionet et al., 2014). Initial screening for
ceramides for which information on speciﬁc transition ions
suitable for mass spectrometric analysis was available, was
based on the data reported by Masukawa et al (2008).
Analysis of whole skin lipid extracts indicated the presence of
ceramides with sphingosine, dihydrosphingosine, phytosphin-
gosine, and 6-hydroxy sphingosine bases, and non-hydroxy,
alpha-hydroxy, or ester-linked omega hydroxy fatty acids,
belonging to 11 of the 15 ceramide families currently identi-
ﬁed (Rabionet et al., 2014)––namely, CER[NS], CER[AS], CER
[NH], CER[AH], CER[NP], CER[AP], CER[NDS], CER[ADS],
CER[EOP], CER[EOS], and CER[EOH]. Lack of commercially
available appropriate synthetic standards did not permit
identiﬁcation of individual species. We therefore focused on
non-hydroxylated ceramides of the CER[NS] family and
phosphorylated ceramides, sphingoid bases, and phosphorylated
base species that could be analyzed using 17-carbon-containing
species as internal standards (Figure 2b and Supplementary
Table S1 online). Further to their role in epidermal barrier
function, the CER[NS] family includes bioactive medium-
chain (40-48-carbon) non-hydroxylated ceramides involved
in cutaneous inﬂammation (Uchida, 2014).
Overall, we identiﬁed two sphingoid bases––18-carbon
sphingosine (C18 S) and 18- carbon dihydrosphingosine (C18
DS)––and their phosphorylated forms 18-carbon sphingosine-
1-phosphate (C18 S1P) and 18-carbon dihydrosphingosine-1-
phosphate (C18 DS1P). We also found 13 CER[NS] ceramides
and four phosphorylated ceramides with long-chain non-
hydroxy fatty acids (22–26 carbons) and sphingoid bases with
16–24 carbons. With the exception of phosphorylated
ceramides that were expressed at similar levels, the epidermis
showed greater expression of all these sphingolipids com-
pared with the dermis. However, high inter-individual varia-
bility meant there was limited statistical signiﬁcance,
with only two ceramide species, CER[N(26)S(16)] and CER
[N(24)S(20)] (P= 0.01, P=0.005, respectively), two phos-
phorylated bases (C18S1P, C18DS1P, P=0.024 and
P=0.018, respectively), and one sphingoid base (C18DS,
P=0.003) being statistically signiﬁcantly higher in the
epidermis (Figure 2b). Of the sphingolipid species found
in blister ﬂuid, the majority were in similar proportions
to the dermis and epidermis (Figure 2b). However, some
species were at noticeably low levels in the blister ﬂuid,
including C18S and the largest ceramides measured
(CER[N(26)S(16)], CER[N(24)S(21)], CER[N(25)S(22)], and
CER[N(24)S(24)]).
Contribution of cutaneous fatty acids
The fatty acid precursors of the eicosanoids and NAE reported
here comprise 77.1% and 61.9% of fatty acids in the dermis
and epidermis, respectively (Figure 3d). Other, non-precursor,
fatty acids make up the remainder (Supplementary Table S2
online). Despite similar proportions of LA in the dermis and
epidermis (10.7 and 9.6% of total fatty acids, respectively),
the epidermis demonstrated higher levels of the LA–derived 9-
and 13-HODE compared with the dermis (69.7 and 50.3% of
total HFA detected in the dermis and epidermis, respectively),
and this was reﬂected in the composition of blister ﬂuid
(65.2% of total HFA detected in blister ﬂuid) (Figure 3b). The
eicosanoid precursors AA and EPA contributed in all classes
of mediators detected. AA was found at a higher concentra-
tion in the epidermis compared with the dermis (2.7% vs.
0.7% of total, respectively), and this was directly reﬂected in
the higher abundance of AEA in the epidermis and blister ﬂuid
(13.1% and 11.2%, respectively) compared with the dermis
(8.3%). In all cases, AEA and EPEA levels were lower
compared with DHEA (Figure 3c). Although cutaneous DHA
was detected at very low levels in the epidermis and dermis
(0.2% and 0.5%, respectively) and was only a minor
contributor of epidermal, but not dermal, HFA (Figure 3b), it
was detected as DHEA in the dermis, epidermis, and blister
ﬂuid (11.7%,16.5%, and 14.6%, respectively) (Figure 3c). The
high levels of dermal OA (44.8% of total fatty acids) were
reﬂected in the higher abundance of OEA (18.3% of total
dermal NAE), whereas PA, which was the most abundant
fatty acid in the skin, contributed as PEA to almost 40% of the
NAE detected in the dermis, epidermis, and blister ﬂuid
(Figure 3c).
Manipulation of lipid mediators by omega-3 PUFA
supplementation ex vivo
Exogenous provision of EPA did not have a statistically
signiﬁcant effect on the levels of COX–derived PGE2 and
LOX–derived 12-HETE in the dermis or epidermis, although it
induced the formation of PGE3 and 12-HEPE, two less
inﬂammatory eicosanoids that can attenuate PGE2– and 12-
HETE–mediated activities (Figures 4a–d). Conversely, DHA
appeared to inhibit PGE2 with concomitant stimulation of 12-
HETE production, suggesting the diversion of cutaneous AA
from COX to LOX–mediated metabolism. Both EPA and DHA
stimulated the production of AEA, EPEA, and DHEA
in the epidermis and dermis, indicating that their anti-
inﬂammatory activities may be mediated, at least in part, via
the endocannabinoid system (Figures 4e and f). Finally, the
formation of 18-HEPE, 17-HDHA, and 14-HDHA post
supplementation shows that human skin can produce the
biochemical precursors of the anti-inﬂammatory and protec-
tive lipids resolvins (RvE and RvD) and maresins (Figures 4c
and d) (Serhan, 2014).
DISCUSSION
Our ﬁndings demonstrate the ability of both the dermis and
epidermis to produce an array of bioactive lipids that may act
locally or be transported and contribute to cross talk between
these skin compartments. It is noteworthy that despite
differences in their physiology, the dermis and epidermis
produce the same mediators, although signiﬁcant differences
in the levels and ratios of certain species highlight their
varying requirements.
Higher production of AA, DGLA, and EPA-derived epider-
mal prostanoids can be attributed to increased expression
and/or activity of COX isoforms and prostanoid synthases, and
agrees with a higher epidermal concentration of AA (Figure 3),
as well as reports of higher expression of the constitutive
COX-1 in the epidermis (Kragballe et al., 1986). The presence
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of deactivated prostanoids, such as 15-keto-PGE2 and 13,
14-dihydro-15-keto PGE2, shows that the levels of potent pro-
inﬂammatory PG such as PGE2 are under an active control,
a step crucial for successful resolution of inﬂammation.
Although the prostanoids found in blister ﬂuid matched the
epidermal proﬁle (Figure 2a), some minor epidermal species
were not detected, suggesting that skin biopsy samples are
more appropriate when investigating low abundance lipid
mediators. Interestingly, PGJ2 was found in the epidermis, but
not blister ﬂuid, whereas its metabolite 15-deoxy-Δ12,14 PGJ2
was found at high levels in blister ﬂuid but not in the
epidermis or dermis. As 15-deoxy-Δ12,14 PGJ2 is believed to
act as a PPARγ agonist involved in anti-inﬂammatory
proresolving signaling, its presence in blister ﬂuid could
potentially be linked to a cutaneous healing response to the
trauma involved in raising suction blisters (Surh et al., 2011).
The epidermal expression of HFA was also higher, with
LA– and AA–derived species being the predominant media-
tors detected (Figure 2a). High production of 12-HETE
suggests increased expression/activity of 12-LOX and agrees
with reports of three different isozymes highly expressed in
the epidermis (Takahashi et al., 1993; Boeglin et al., 1998;
Muller et al., 2002). 12-HETE has proinﬂammatory and
neutrophil chemotactic properties indicating the potential
involvement of 12-LOX in inﬂammatory skin disease (e.g.
psoriasis) (Fogh et al., 1993; Baer et al., 1995). Although the
LA-derived 15-LOX product 13-HODE was found at higher
levels in the epidermis, the AA-derived 15-HETE and DGLA-
derived 15-HETrE were present at similar levels in both
compartments, albeit at lower concentrations, in accordance
with the much lower levels of their precursor fatty acids
(Figure 3). 15-LOX products have anti-inﬂammatory activities
and may have a speciﬁc role in the cross talk of the dermis
and the epidermis, as demonstrated by the regulation
exhibited by dermal 15-HETE on epidermal 12-LOX activity
(Kragballe et al., 1986; Yoo et al., 2008). In addition, hair
follicles, found in the dermis, are known to express high levels
of a 15 S-LOX (Brash et al., 1997) that preferentially
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metabolizes AA over LA. Although the abdominal skin used in
this study was not densely populated with hair, the presence
of hair follicles in the dermis could possibly explain why 15-
HETE was present at comparable levels in the dermis and
epidermis but 13-HODE was not. Finally, the 5-LOX product
5-HETE was found at very low levels in both skin compart-
ments, suggesting a low cutaneous expression of 5-LOX. This
supports current understanding that 5-LOX–derived leuko-
trienes, found in inﬂammatory skin disease such as psoriasis,
are derived from inﬁltrating immune cells rather than resident
cells (Ford-Hutchinson, 1993; Sadik et al., 2014).
The signiﬁcantly higher epidermal levels of the endocan-
nabinoid AEA, and the NAE species EPEA and DHEA, are of
interest, indicating their potential roles in homeostatic
processes in resting skin. AEA has been reported to regulate
keratinocyte proliferation, sebum production, and melano-
genesis (Conconi et al., 1996; Dobrosi et al., 2008; Pucci
et al., 2012). It is noteworthy that, although all HFA
derivatives of DHA contributed o2% of total class species,
DHEA was one of the main NAE detected (11–16% of total;
Figure 3c). DHEA is an endocannabinoid-like molecule
exhibiting weak afﬁnities for cannabinoid receptors (Kim
and Spector, 2013). EPEA and DHEA have anti-inﬂammatory
properties, reducing lipopolysaccharide (LPS)–induced IL-6
and monocyte chemotactic protein (MCP)-1 production in
adipocytes, and LPS–induced ˙NO production in macro-
phages (Satoh et al., 2006; Uchida, 2014), and may operate
similar anti-inﬂammatory effects in the skin. The saturated
NAE species, PEA and OEA, derivatives of palmitic (PA) and
oleic (OA) acid, respectively, were found at equally high
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levels in both the dermis and epidermis. PEA is known to
suppress cutaneous mast cell activity and may confer anti-
inﬂammatory activity (Mizutani et al., 2009; Wang and Ueda,
2009). OEA is known to affect food intake and the sleep-wake
cycle, but its role in the skin is unknown (Honma et al., 2005).
Supplementation with exogenous EPA and DHA showed that
their cutaneous metabolism alters the proﬁle of dermal and
epidermal lipids, stimulating the production of anti-inﬂam-
matory species including COX– and LOX–derived products,
and NAE (Figure 4). This provides information on how the skin
can respond to nutritional interventions and suggests that
n-3PUFA can also create a protective and pro-resolving
environment, as supported by the identiﬁcation of biochem-
ical precursors for protectins and resolvins in the skin.
Ceramides are components of the stratum corneum
involved in epidermal barrier function, particularly the
omega-esteriﬁed species with long acyl chains, with more
than 300 species identiﬁed to date (Behne et al., 2000; van
Smeden et al., 2011; Iwai et al., 2012; Rabionet et al., 2014).
In this study, we focus our attention particularly on the family
of non-hydroxylated medium-chain ceramides that can be
found in cellular membranes, and, notably, we demonstrate
the presence of 21 species in the epidermis, as well as in the
dermis and blister ﬂuid. This suggests their wider involvement
in epidermal and dermal function, where they may mediate
activities including regulation of apoptosis and inﬂammation
(Stiban et al., 2008; Maceyka and Spiegel, 2014). Blister ﬂuid
showed lower expression of the longest ceramides measured,
possibly indicating impaired release of these species during
the blister formation. Further work is indicated to elucidate
the prevalence of these non-hydroxylated species in epider-
mal and dermal cells and explain the intriguing ﬁnding of
their comparable abundance in both skin compartments.
Phosphorylated ceramides were also present in the dermis
and epidermis at equally high concentrations, suggesting that
they originate from cellular membranes and are not restricted
to the differentiated epidermis. This is indicative of an active
signaling role in both compartments that may include the
ceramide-1-phosphate– and sphingosine-1-phosphate–mediated
activation of cutaneous PLA2 (Chalfant and Spiegel, 2005).
Ceramide-1-phosphate has also been recently reported to be
involved in wound healing through acting in concert
with eicosanoid production (Wijesinghe et al., 2014), and
sphingosine-1-phosphate is a modulator of cutaneous immu-
nity (Herzinger et al., 2007). In this study, we focused on the
more common 18-carbon sphingosine and dihydrosphingo-
sine bases and found that the free sphingoid base C18DS,
known to promote keratinocyte differentiation (Paragh et al.,
2008), demonstrated increased expression in the epidermis
(Figure 2b). Future investigations could include analysis of the
less–abundant sphingosines and dihydrosphingosines with
other carbon chain-lengths, as well as the phytosphingosine
and 6-hydroxy sphingosine bases.
A limitation of the present study is the method used to
separate the dermis from the epidermis––i.e. physical separa-
tion. The commonly used methods for their separation along
the dermo–epidermal junction rely on long incubation
with salts or enzymes, or rapid transition from high to low
temperatures, to degrade the basement membrane, and are
inappropriate for the purposes of this study as they can induce
oxidation or thermal degradation of the lipid mediators (Zhang
et al., 2003; Oakford et al., 2011). Although physical separation
of the dermis and the epidermis resulted in slight dermal
contamination of the epidermis, care was taken that the
less cellular dermis would remain completely free of any
epidermal component. Following analysis, it was found that
differences in lipid expression between the two compartments
were reliably identiﬁed.
Overall, this study shows that the dermis produces a wide
range of lipid mediators and this production may be an
important biochemical support for the epidermis, acting as an
intermediary between the epidermal interface with the
external environment and the subcutaneous circulatory and
lymphatic systems. To our knowledge, this is the most
complete analysis of bioactive lipid mediators in human skin
to be reported. Proﬁles of lipid mediators can support the
characterization of COX, LOX, and CYP isoforms, whose
activity and pattern of expression depend on post-transla-
tional modiﬁcations and may contribute to cutaneous
disorders (Aguiar et al., 2005; Kuhn and O'Donnell, 2006;
Mbonye and Song, 2009). We have also shown an ability to
manipulate the balance of bioactive lipids in favor of the
protective omega-3–derived species, with implications for
their mode of action in skin health and disease. Finally, direct
comparison of lipid mediators found in suction blister ﬂuid, a
widely used technique for sampling cutaneous intercellular
ﬂuid, with skin lipid proﬁles, provides conﬁrmatory informa-
tion on study design to explore the potency and importance of
lipid mediators in skin biology.
MATERIALS AND METHODS
Tissue samples
Biobank skin. Skin samples were obtained from a biobank
(Ethical Tissue, University of Bradford, Bradford, UK) with full
ethical approval (Leeds East Research Ethics Committee reference
07/H1306/98+5). The skin was provided by 8 healthy donors
(6 female, 2 male; 30–60 years; white Caucasian), undergoing
elective abdominoplastic surgery, delivered to the biobank
within 1 h of the operation. The tissue was washed and the
adipose layer removed. Punch biopsies (3 mm) were cut, snap
frozen and stored at −80 ºC, or were cultured ex vivo. Ex vivo
culture was performed in DMEM containing 100 Uml− 1 peni-
cillin, 100 μgml− 1 streptomycin, and 1.4 mM Ca2+(Promocell,
Heidelberg, Germany), with or without the addition of EPA or
DHA (50 μM) (Sigma Aldrich, Poole, UK), for 3 days (Tavakkol
et al., 1999). For lipidomics assays, three punch biopsies per
donor were used. Before analysis, the skin was divided into the
dermis and epidermis (on ice, by scalpel, with the aid of visual
inspection at × 40 magniﬁcation). Although epidermal samples
demonstrated minor contamination with dermal tissue, care was
taken that the dermal tissue was not contaminated with the
epidermal tissue.
Skin suction blister ﬂuid and punch biopsies. Healthy human
volunteers (n=8; all females; 28–56 years; white Caucasian)
were recruited by the Photobiology Unit, Dermatology Centre,
Salford Royal Hospital, Manchester, UK. Ethical approval was
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obtained from the North Manchester Research Ethics Committee
(reference 08/H1006/79). Written informed consent was obtained
from participants and the study adhered to Declaration of
Helsinki principles. Volunteers provided 5mm skin punch
biopsies and suction blisters from buttock skin for these analyses.
Punch biopsy dermis and epidermis were separated as described
above, and samples used for total fatty acid analysis. Suction
blistering was performed using suction cups with a 1-cm central
aperture as described previously (Rhodes et al., 2009). Skin
blister ﬂuid was aspirated with a 23-gauge needle, snap-frozen in
liquid nitrogen, and stored at − 80ºC.
Eicosanoid extraction and analysis
Skin samples (30–60mg) and blister ﬂuid samples (40–90 μl) were
extracted using ice-cold 15% (v/v) methanol solution. 12-HETE-d8
and PGB2-d4 (Cayman Chemicals, Ann Arbor, MI, USA) were used
as internal standards, as published before (Masoodi and Nicolaou,
2006; Masoodi et al., 2008; Massey and Nicolaou, 2013).The
extracts were semi-puriﬁed by SPE cartridges (C18-E; Phenomenex,
Macclesﬁeld, UK); the assay recovery was estimated at 96–98%. LC/
ESI-MS/MS was performed on an HPLC pump (Waters Alliance 2695)
coupled to an electrospray ionization triple quadrupole mass
spectrometer (Quattro Ultima, Waters, Elstree, Hertfordshire, UK).
Results are expressed as pg per mg protein (skin) or pg ml− 1
(blister ﬂuid), estimated using calibration lines covering the range
0.02–20 ngml−1. Detailed description of the experimental protocol
is provided as Supplementary Methods SM1 online.
Endocannabinoid and NAE extraction and analysis
Skin samples (30–60mg) and blister ﬂuid samples (40–90 μl) were
extracted using ice-cold 2:1 (v/v) chloroform/methanol. Arachido-
noyl EA-d8 and 2-arachidonoyl glycerol-d8 (Cayman Chemicals,
Ann Arbor, MI) were used as internal standards. Lipid extracts were
analyzed by LC/ESI-MS/MS. Recovery was estimated at 91%. Results
are expressed as pg per mg protein (skin) or pg ml− 1 (blister ﬂuid),
estimated using calibration lines covering the range 0.02–50 ng-
ml− 1. Detailed description of the experimental protocol is provided
as Supplementary Methods SM2 online.
Sphingolipid extraction and analysis
Skin samples (30–60mg) and blister ﬂuid samples (40–90 μl) were
extracted using ice-cold isopropanol:water:ethyl acetate (30:10:60;
v/v/v). The following internal standards were used: C17 S (used for
C18 S), C17 DS (used for C18 DS), C17 S1P (used for C18 S1P), C17
DS1P (used for C18 DS1P), d18:1/12:0 C1P (used for all C1P
species), and C25 Cer (used for all CER[NS] species) (Ceramide/
Sphingoid Internal Standard Mixture I, Avanti Polar Lipids, Alabaster,
AL). The resulting lipid extracts were analyzed by LC/ESI-MS/MS
(Bielawski et al., 2006; Kelly et al., 2011). The assay recovery was
estimated at 75–79%. Results are expressed as pmol per g protein
(skin) or pmol μl−1 (blister ﬂuid), relative to the appropriate internal
standard (covering the range 0.005–8.0 nmol ml− 1). Detailed des-
cription of the experimental protocol is provided as Supplementary
Methods SM3 online.
Fatty acid analysis
Fatty acids were analyzed by gas chromatography (GC) in the dermis
and epidermis as previously described (Pilkington et al., 2014).
Results are expressed as a percentage of total fatty acids. Detailed
description of the experimental protocol is provided as Supple-
mentary Methods SM4 online.
Protein content
During lipid extractions, protein pellets were retained for analysis of
protein content using a standard Bradford protein assay kit (Bio-Rad,
Hemel Hempstead, UK) (Bradford, 1976). Proteins were extracted
using 1M NaOH and analyzed within the linear range of the assay to
ensure accuracy.
Statistical analysis
Statistical analyses of lipid mediator expression were performed using
repeated measures ANOVAs with Greenhouse-Geisser corrections
and Bonferroni post-hoc tests. Analyses were conducted using SPSS
20 software, and Po0.05 was considered signiﬁcant.
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